All In Biotech

NDA 021210 · Stevens J

Unithroid

Levothyroxine Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Dec 10, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 21, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

102,450

70,776 serious, 8,406 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: Thyroid hormones, including Levothyroxine Sodium Tablets, USP, either alone or with other therapeutic agents, should not be used for the treatment of obesity for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

What it is approved for

From the label in effect Jun 4, 2026.

INDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression - In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic Iymphocytic thyroiditis (Hashimoto's thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ), and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

12 products under this application
  • UNITHROID · LEVOTHYROXINE SODIUM 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • UNITHROID · LEVOTHYROXINE SODIUM 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue8,376
  • nausea7,357
  • diarrhoea6,656
  • headache6,480
  • dyspnoea6,385
  • drug ineffective5,502
  • pain5,395
  • dizziness5,136
  • vomiting4,585
  • asthenia4,398
  • off label use4,180
  • fall4,153

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,059
20052,025
20062,195
20072,773
20084,028
20093,842
20104,322
20116,155
20126,837
20131,415
20141,740
20152,411
20163,188
20173,647
20184,174
20194,062
20205,493
20215,861
20227,465
20237,039
20247,410
20258,338
20265,970

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Unithroid (Levothyroxine Sodium)

2024 spending

$4.1M

Beneficiaries

26,303

94,138 claims

Per beneficiary

$158

$0.58 per unit

View as table
YearSpending
2020$1,716,519
2021$2,006,354
2022$2,246,627
2023$2,758,840
2024$4,144,726

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 611 on PubMed

Sponsor: Stevens J

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.